NovaBridge Biosciences (NBP)
NasdaqGM · USD · Healthcare · Biotechnology
$1.22 (-11.31%) as of
Key statistics
- Market cap
- 140.94M
- Forward P/E
- -1.15
- EPS (TTM)
- -0.6900
- Dividend yield
- 0.00%
- 52-week range
- 1.2100 – 5.1900
- Beta
- 1.60
- Profit margin
- 0.00%
- Analyst target
- $9.00
- Volume
- 816.73k
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Rockville, MD, United States
- Employees
- 30
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.